MONTREAL, Sept. 12, 2016 /CNW Telbec/ - BioAmber Inc. (NYSE:
BIOA), is pleased to announce that it has closed on a $19.2 million (CDN $25
million) loan from Bridging Finance Inc., acting as sub-advisor to the Sprott Bridging Income Fund LP. Proceeds from the
loan will be used to retire an $8 million loan from Tennenbaum Capital Partners, with the balance
applied to general corporate purposes. The loan does not contain any convertible features or warrants.
Mario Saucier, Chief Financial Officer of BioAmber stated: "This non-dilutive loan from Bridging
Finance is a strong endorsement of our facility, technology and team, and has allowed us to both lower our financing costs and
strengthen our balance sheet. We remain committed to rewarding the confidence that Bridging Finance and our shareholders have shown
in us as we ramp-up towards full capacity".
About Bridging Finance Inc.
Bridging Finance is a privately held Canadian company providing middle-market North American companies with alternatives
to the financing options offered by traditional lenders. Lending proceeds are used by companies to address short-term needs such as
restructuring existing debt, providing working capital for growth, supporting inventory purchases and financing expenditures and
acquisitions/buyouts. Bridging Finance is the Sub-Advisor to the Sprott Bridging Income Fund LP. Bridging Finance also offers
portfolio management services for institutional and family office clients.
About BioAmber
BioAmber (NYSE: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and
catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products
including plastics, paints, textiles, food additives and personal care products. For more information visit www.bio-amber.com
Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and
assumptions. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek,"
"will," "may" or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or
occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward-
looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak
only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. For additional disclosure regarding these and other risks faced
by BioAmber, see disclosures contained in BioAmber's public filings with the SEC including, the "Risk Factors" section of
BioAmber's most recent Annual Report on Form 10-K and the recent quarterly reports on Form 10-Q.
SOURCE BioAmber Inc.
